Laboratorios Farmaceuticos ROVI Market Cap ($3.74 Billion)
Market Cap & Net Worth: Laboratorios Farmaceuticos ROVI (ROVI)
Laboratorios Farmaceuticos ROVI market cap. Laboratorios Farmaceuticos ROVI (MC:ROVI) has a market capitalization of $3.74 Billion (€3.20 Billion) as of October 31, 2026. Listed on the MC stock exchange, this Spain-based company holds position #4151 globally and #34 in its home market, demonstrating a 5.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Laboratorios Farmaceuticos ROVI's stock price €62.55 by its total outstanding shares 51149498 (51.15 Million).
Laboratorios Farmaceuticos ROVI Market Cap History (2015–2026)
Laboratorios Farmaceuticos ROVI market cap history from 2015 to 2026. Data shows growth from $793.36 Million to $3.74 Billion (15.27% CAGR). Check Laboratorios Farmaceuticos ROVI stock price for real-time trading data and today's change.
Index Memberships
Laboratorios Farmaceuticos ROVI is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
IBEX 35 Index
IBEX
|
$1.08 Trillion | 0.35% | #30 of 34 |
Weight: Laboratorios Farmaceuticos ROVI's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Laboratorios Farmaceuticos ROVI Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Laboratorios Farmaceuticos ROVI's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Laboratorios Farmaceuticos ROVI cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
4.93x
Laboratorios Farmaceuticos ROVI's market cap is 4.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
27.50x
Laboratorios Farmaceuticos ROVI's market cap is 27.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $793.36 Million | $246.01 Million | $19.81 Million | 3.22x | 40.05x |
| 2016 | $683.18 Million | $265.17 Million | $26.09 Million | 2.58x | 26.19x |
| 2017 | $874.72 Million | $275.65 Million | $17.24 Million | 3.17x | 50.73x |
| 2018 | $981.54 Million | $303.20 Million | $17.89 Million | 3.24x | 54.85x |
| 2019 | $1.38 Billion | $381.31 Million | $39.27 Million | 3.61x | 35.06x |
| 2020 | $2.15 Billion | $419.96 Million | $61.06 Million | 5.11x | 35.16x |
| 2021 | $4.20 Billion | $648.68 Million | $153.08 Million | 6.48x | 27.45x |
| 2022 | $2.08 Billion | $817.70 Million | $199.67 Million | 2.54x | 10.42x |
| 2023 | $3.56 Billion | $829.51 Million | $170.34 Million | 4.29x | 20.91x |
| 2024 | $3.76 Billion | $763.75 Million | $136.88 Million | 4.93x | 27.50x |
Competitor Companies of ROVI by Market Capitalization
Companies near Laboratorios Farmaceuticos ROVI in the global market cap rankings as of October 31, 2026. See Laboratorios Farmaceuticos ROVI (ROVI) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to Laboratorios Farmaceuticos ROVI by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Laboratorios Farmaceuticos ROVI (2015–2026)
Market capitalization of Laboratorios Farmaceuticos ROVI from 2015 to today. Between 2015 and today, Laboratorios Farmaceuticos ROVI's market cap moved from $793.36 Million to $ 3.74 Billion, with a yearly change of 15.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.74 Billion | -1.50% |
| 2025 | €3.80 Billion | +0.87% |
| 2024 | €3.76 Billion | +5.67% |
| 2023 | €3.56 Billion | +71.18% |
| 2022 | €2.08 Billion | -50.47% |
| 2021 | €4.20 Billion | +95.75% |
| 2020 | €2.15 Billion | +55.89% |
| 2019 | €1.38 Billion | +40.28% |
| 2018 | €981.54 Million | +12.21% |
| 2017 | €874.72 Million | +28.04% |
| 2016 | €683.18 Million | -13.89% |
| 2015 | €793.36 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Laboratorios Farmaceuticos ROVI was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.74 Billion USD |
| MoneyControl | $3.74 Billion USD |
| MarketWatch | $3.74 Billion USD |
| marketcap.company | $3.74 Billion USD |
| Reuters | $3.74 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Laboratorios Farmaceuticos ROVI
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Trypti… Read more